These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG; Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037 [TBL] [Abstract][Full Text] [Related]
8. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965 [TBL] [Abstract][Full Text] [Related]
9. Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. Verstockt B; Pivorunas V; Al Mahi N; Smaoui N; Guay H; Kennedy NA; Goodhand JR; Lin S; Bai BYH; Hanauer SB; Ferrante M; Panés J; Vermeire S J Crohns Colitis; 2024 Apr; 18(4):493-505. PubMed ID: 37801628 [TBL] [Abstract][Full Text] [Related]
10. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Suzuki Y; Motoya S; Hanai H; Matsumoto T; Hibi T; Robinson AM; Mostafa NM; Chao J; Arora V; Camez A; Thakkar RB; Watanabe M J Gastroenterol; 2014 Feb; 49(2):283-94. PubMed ID: 24363029 [TBL] [Abstract][Full Text] [Related]
13. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251 [TBL] [Abstract][Full Text] [Related]
14. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Wolf D; D'Haens G; Sandborn WJ; Colombel JF; Van Assche G; Robinson AM; Lazar A; Zhou Q; Petersson J; Thakkar RB Aliment Pharmacol Ther; 2014 Sep; 40(5):486-97. PubMed ID: 25041859 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379 [TBL] [Abstract][Full Text] [Related]
17. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574 [TBL] [Abstract][Full Text] [Related]
18. Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial. Stodtmann S; Chen MJ; Siovitz L; Bereswill M; Lazar A; Croft N; Kierkus J; Faubion WA; Mostafa NM J Crohns Colitis; 2022 Nov; 16(10):1551-1561. PubMed ID: 35526272 [TBL] [Abstract][Full Text] [Related]
19. Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Suzuki Y; Motoya S; Hanai H; Hibi T; Nakamura S; Lazar A; Robinson AM; Skup M; Mostafa NM; Huang B; Thakkar R; Watanabe M J Gastroenterol; 2017 Sep; 52(9):1031-1040. PubMed ID: 28321512 [TBL] [Abstract][Full Text] [Related]